Stock Research: Aclaris Therapeutics

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Aclaris Therapeutics

NasdaqGS:ACRS US00461U1051
26
  • Value
    97
  • Growth
    71
  • Safety
    Safety
    12
  • Combined
    54
  • Sentiment
    34
  • 360° View
    360° View
    26
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing drug candidates for immuno-inflammatory diseases. The company operates in the biotechnology industry, specifically focusing on therapeutics and contract research. Aclaris Therapeutics is focused on developing therapies to address unmet needs for immuno-inflammatory diseases. In the last fiscal year, the company had a market cap of $167 million, profits of $3 million, and revenue of $19 million with 64 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 26 (better than 26% compared with alternatives), overall professional sentiment and financial characteristics for the stock Aclaris Therapeutics are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Aclaris Therapeutics. The consolidated Growth Rank has a good rank of 71, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 71% of competitors in the same industry. In addition, the consolidated Safety Rank has a safer rank of 97 which means that the company has a financing structure that is safer than 97% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the consolidated Value Rank has a less desirable rank of 12 which means that the share price of Aclaris Therapeutics is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is higher than for 88% of alternative stocks in the same industry. The consolidated Sentiment Rank also has a low rank of 34, which means that professional investors are more pessimistic about the stock than for 66% of alternative investment opportunities. ...read more

more
Index
NASDAQ
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
12 16 47 7
Growth
71 93 9 69
Safety
Safety
97 97 91 91
Sentiment
34 54 10 18
360° View
360° View
26 26 1 16
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
91 95 26 91
Opinions Change
50 38 64 50
Pro Holdings
n/a 61 6 8
Market Pulse
11 13 24 16
Sentiment
34 54 10 18
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
12 16 47 7
Growth
71 93 9 69
Safety Safety
97 97 91 91
Combined
54 54 82 82
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
14 14 14 14
Price vs. Earnings (P/E)
3 3 20 2
Price vs. Book (P/B)
53 53 84 40
Dividend Yield
1 1 1 1
Value
12 16 47 7
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
4 43 13 27
Profit Growth
67 72 15 16
Capital Growth
85 92 90 91
Stock Returns
89 95 3 99
Growth
71 93 9 69
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
100 100 100 69
Refinancing
77 75 95 55
Liquidity
1 1 14 14
Safety Safety
97 97 91 91

Similar Stocks

Discover high‑ranked alternatives to Aclaris Therapeutics and broaden your portfolio horizons.

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Intuit

NasdaqGS:INTU
Country: USA
Industry: Application Software
Size: X-Large
Full Stock Analysis

Lithia Motors

NYSE:LAD
Country: USA
Industry: Automotive Retail
Size: X-Large
Full Stock Analysis

Micron

NasdaqGS:MU
Country: USA
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.